|1.||Saha, Debabrata: 1 article (03/2013)|
|2.||Yu, Lan: 1 article (03/2013)|
|3.||Choy, Hak: 1 article (03/2013)|
|4.||Tumati, Vasu: 1 article (03/2013)|
|5.||Chen, Benjamin: 1 article (03/2013)|
|6.||Kumar, Subashri: 1 article (03/2013)|
|7.||O'Bryant, Cindy L: 1 article (02/2013)|
|8.||Thompson, Lisa A: 1 article (02/2013)|
|9.||Kim, Miryoung: 1 article (02/2013)|
|10.||Wenger, Sarah D: 1 article (02/2013)|
03/01/2013 - "Although PF-02341066 is an effective therapy able to suppress tumor growth in tumors that exhibit positivity for either EML4-ALK or c-Met, it did not affect the intrinsic radiation response of tumor cell lines. "
03/01/2013 - "Treatment of NSCLC cells with either PF-02341066 alone or PF-02341066 + IR did not significantly alter cellular radiosensitivity, DNA repair kinetics and cell cycle distribution; no significant enhancement of tumor growth delay was noted in response to the combined treatment of PF-02341066 + IR. "
03/01/2013 - "PF-02341066 (crizotinib) is a novel dual c-Met and EML4-ALK inhibitor, and preclinical studies have shown that treatment with ALK inhibitors leads to drastic tumor regression in xenograft models. "
|2.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
|3.||Neoplasm Metastasis (Metastasis)
|1.||Heterologous Transplantation (Xenotransplantation)